Using this model, BRB administration over a 5-week period led to several noteworthy outcomes, including a reduction in tumor growth, an increased influx of anti-tumoral T cells into the tumor microenvironment, and the augmentation of anti-tumoral cytotoxic CD8+ T cell activity, characterized by increased expression of granzyme B and perforin (Figure 2) [27]. Here, GZMB is linked to neoplasm.